STOCK TITAN

MediciNova names CEO Yuichi Iwaki interim CFO

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

MediciNova, Inc. (MNOV) reported that Jason Kruger resigned as chief financial officer, effective immediately on November 10, 2026. Kruger had served as principal financial officer and principal accounting officer and will continue supporting accounting and assist with the transition.

On November 11, 2026, the board appointed President and Chief Executive Officer Yuichi Iwaki, M.D., Ph.D., as interim chief financial officer, effective immediately until a successor is appointed. Iwaki will also serve as acting principal financial and accounting officer while retaining his president, CEO and board roles. He previously served as acting CFO from November 2013 to April 2014. He will receive no additional compensation for the interim appointment, and his existing employment-agreement terms are unchanged.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Interim CFO appointment November 11, 2026 Yuichi Iwaki's appointment date; effective immediately until a successor is appointed
Yuichi Iwaki's age 76 years Age stated in the appointment disclosure
principal financial officer regulatory
"served as the Company’s principal financial officer"
The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.
principal accounting officer regulatory
"served as the Company’s principal accounting officer"
The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is MNOV's interim CFO?

Yuichi Iwaki, M.D., Ph.D., MediciNova's president and chief executive officer, was appointed interim CFO on November 11, 2026, effective immediately until a successor is appointed. He will continue as president, CEO and a board member.

Will MNOV CEO Yuichi Iwaki receive extra compensation as interim CFO?

No. Iwaki will receive no additional compensation for the interim CFO appointment, and no changes were made to the terms of his existing employment agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001226616falseDE00012266162026-11-102026-11-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2026

MEDICINOVA, INC.

(Exact name of registrant as specified in its charter)

DELAWARE

001-33185

33-0927979

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

 

4275 EXECUTIVE SQUARE,
SUITE 300, LA JOLLA, CA

92037

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (858) 373-1500

Not applicable.

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Common Stock, $0.001 par value

MNOV

The Nasdaq Stock Market LLC

(Title of each class)

(Trading
symbol(s))

(Name of each exchange
on which registered)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

 

 


 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Chief Financial Officer

On November 10, 2026, Jason Kruger notified MediciNova, Inc. (the “Company”) of his resignation as Chief Financial Officer of the Company, effective immediately. Mr. Kruger had served as the Company’s principal financial officer and principal accounting officer. Mr. Kruger’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr. Kruger has indicated that he will continue to support the Company’s accounting efforts following his resignation and will assist in the orderly transition of his responsibilities.

Appointment of Interim Chief Financial Officer

In connection with Mr. Kruger’s resignation, on November 11, 2026, the Board of Directors of the Company (the “Board”) appointed Yuichi Iwaki, M.D., Ph.D., the Company’s President and Chief Executive Officer, to serve as the Company’s interim Chief Financial Officer, effective immediately, until a successor is appointed. In this role, Dr. Iwaki will serve as the Company’s acting principal financial officer and acting principal accounting officer. Dr. Iwaki will continue to serve as the Company’s President and Chief Executive Officer and principal executive officer, and as a member of the Board.

Dr. Iwaki, age 76, is a founder of the Company and served as the Chairman of the Board from the Company’s inception in September 2000 to March 2007, was appointed as Executive Chairman in July 2005, Chief Executive Officer in September 2005 and President and Chief Executive Officer in March 2006. Dr. Iwaki previously served as the Company’s Acting Chief Financial Officer from November 2013 to April 2014. Dr. Iwaki was a member of the board of directors of Avigen, Inc. from 1994 to 2008. He holds a professorship at the University of Southern California School of Medicine in the Department of Urology and was Director of the Transplantation Immunology and Immunogenetic Laboratory from 1992 through March 2025. Dr. Iwaki is also a visiting professor at the Toho University School of Medicine. Prior to joining the faculty at the University of Southern California School of Medicine, Dr. Iwaki held two professorships at the University of Pittsburgh School of Medicine in the Departments of Surgery and Pathology from 1989 through 1991. Dr. Iwaki received both his M.D. and Ph.D. degrees from Sapporo Medical School in Sapporo, Japan.

There are no arrangements or understandings between Dr. Iwaki and any other person pursuant to which he was appointed as interim Chief Financial Officer. There are no family relationships between Dr. Iwaki and any director or executive officer of the Company, and Dr. Iwaki has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Dr. Iwaki will not receive any additional compensation in connection with his appointment as interim Chief Financial Officer, and no changes were made to the terms of his existing employment agreement with the Company in connection with this appointment.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

MEDICINOVA, INC.

 

 

 

 

By:

/s/ Yuichi Iwaki

Yuichi Iwaki

 

 

President and Chief Executive Officer

Date: November 16, 2026

 

 

 

 

 


Filing Exhibits & Attachments

1 document

Keep reading